This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synta's Lung Cancer Drug Struggles to Remain Relevant

CHICAGO ( TheStreet) -- The efficacy of Synta Pharmaceuticals' (SNTA) lung cancer drug ganetespib is weakening over time, which should raise even more concerns about the ongoing phase III clinical trial.

Snyta shares are down 17% to $6.15 in early Monday trading.

The latest update from the phase II "Galaxy-1" study, which compares ganetespib plus docetaxel against docetaxel alone in second-line non-small cell lung cancer, are being presented Monday during the American Society of Clinical Oncology (ASCO) annual meeting:

The overall survival hazard ratio for the 252 adenocarcinoma patients is 0.82, which translates into an 18 percent reduction in the risk of death. Median overall survival for ganetespib/docetaxel was 9.8 months compared to 7.4 months for docetaxel.

The result was not statistically significant and worse than the previous update of the Galaxy-1 study presented last September when the hazard ratio was 0.69, or a 31 percent reduction in the risk of death.

Synta didn't wait for final data from Galaxy-1 before starting to enroll patients in a phase III study of ganetespib in second-line lung cancer. This larger, Galaxy-2 study excludes patients who are deemed to be "rapid progressors" -- defined as patients who responded poorly to first-line therapy. In order to qualify to entry into Galaxy-2, patients have to be stable (no tumor growth) following first-line therapy for at least six months. Call these patients "normal progressors" for lack of a better term.

On Monday, Synta released an update on the subset of 176 "normal progressors" from the Galaxy-1 study. Again, the survival trend narrowed.

The latest overall survival hazard ratio is 0.61, or a 39 percent reduction in the risk of death. At the median, ganetespib/docetaxale increased overall survival by 4.3 months over docetaxel alone (10.7 months versus 6.4 months.)

Last September, the hazard ratio was 0.37, or a 63 percent reduction in the risk of death.

Investors have tended to view ganetespib's chances of success with a lot of skepticism because claims the drug would work better in certain targeted subsets of lung cancer patients (elevated LDH or KRAS mutants) have not panned out. The narrowing survival trend from the Galaxy-1 study in data-mined subsets of patients isn't likely to bolster anyone's confidence in Synta's ability to deliver a positive outcome from the pivotal Galaxy-2 study.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMY $61.71 1.10%
MRK $50.04 1.80%
SNTA $0.20 1.60%
AAPL $95.24 0.26%
FB $102.53 3.00%


Chart of I:DJI
DOW 16,044.27 +29.89 0.19%
S&P 500 1,866.09 +13.88 0.75%
NASDAQ 4,329.1020 +60.3390 1.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs